Spots Global Cancer Trial Database for sotorasib
Every month we try and update this database with for sotorasib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | NCT04720976 | Solid Tumor NSCLC | JAB-3312 Binimetinib Pembrolizumab Sotorasib Osimertinib | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Ladarixin With Sotorasib in Advanced NSCLC - Phase II | NCT05815186 | Advanced Non-sm... | Sotorasib Ladarixin | 18 Years - 100 Years | NYU Langone Health | |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy | NCT05398094 | Non-small Cell ... KRAS P.G12C | Sotorasib | 18 Years - | Fundación GECP | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | NCT05251038 | Pancreatic Canc... Unresectable Pa... Metastatic Panc... KRAS P.G12C | Sotorasib Liposomal Irino... 5 Fluorouracil ... Leucovorin (LV) Gemcitabine (GE... Nab paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | NCT04625647 | Lung Adenocarci... Lung Non-Small ... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Sotorasib | 18 Years - | SWOG Cancer Research Network | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | NCT04185883 | Advanced Solid ... Kirsten Rat Sar... | Sotorasib Trametinib RMC-4630 Afatinib Pembrolizumab Panitumumab Carboplatin, pe... Atezolizumab Palbociclib MVASI® (bevaciz... TNO155 IV Chemotherapy... IV Chemotherapy... BI 1701963 AMG 404 Everolimus | 18 Years - 100 Years | Amgen | |
| Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants | NCT05045638 | Healthy Partici... | Rosuvastatin Sotorasib | 18 Years - 60 Years | Amgen | |
| VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | NCT05374538 | Non-small Cell ... | VIC-1911 sotorasib | 18 Years - | Vitrac Therapeutics, LLC | |
| VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | NCT05374538 | Non-small Cell ... | VIC-1911 sotorasib | 18 Years - | Vitrac Therapeutics, LLC | |
| AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC | NCT06068153 | Metastatic Non ... KRAS G12C | Sotorasib Lenvatinib | 18 Years - | ETOP IBCSG Partners Foundation | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | NCT05564377 | Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma... | Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib | - | National Cancer Institute (NCI) | |
| Ladarixin With Sotorasib in Advanced NSCLC | NCT05815173 | Advanced Non-sm... | Sotorasib Ladarixin | 18 Years - 100 Years | NYU Langone Health | |
| A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) | NCT06333678 | Non-Small Cell ... | Durvalumab Sotorasib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | NCT06252649 | Metastatic Colo... | FOLFIRI Regimen Sotorasib Panitumumab Bevacizumab-aww... | 18 Years - | Amgen | |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | NCT05638295 | Advanced Malign... Metastatic Mali... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Panitumumab Sotorasib | 18 Years - | National Cancer Institute (NCI) | |
| SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | NCT05480865 | Solid Tumor, Ad... Metastatic Soli... Metastatic NSCL... Non Small Cell ... | BBP-398 sotorasib | 18 Years - 99 Years | Navire Pharma Inc., a BridgeBio company | |
| Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | NCT04092673 | Solid Tumor, Ad... | eFT226 Sotorasib Fulvestrant Abemaciclib Trastuzumab | 18 Years - | Effector Therapeutics | |
| An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib | NCT05451056 | Non Small Cell ... | sotorasib | 19 Years - | Yonsei University | |
| Ladarixin With Sotorasib in Advanced NSCLC - Phase II | NCT05815186 | Advanced Non-sm... | Sotorasib Ladarixin | 18 Years - 100 Years | NYU Langone Health | |
| Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants | NCT05045638 | Healthy Partici... | Rosuvastatin Sotorasib | 18 Years - 60 Years | Amgen | |
| Ladarixin With Sotorasib in Advanced NSCLC | NCT05815173 | Advanced Non-sm... | Sotorasib Ladarixin | 18 Years - 100 Years | NYU Langone Health | |
| RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC | NCT05273047 | Nsclc KRAS P.G12C | 18 Years - 90 Years | Intergroupe Francophone de Cancerologie Thoracique | ||
| AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | NCT06333951 | Thoracic Tumors Non-small Cell ... | AMG 193 Carboplatin Paclitaxel Pembrolizumab Pemetrexed Sotorasib | 18 Years - 100 Years | Amgen | |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | NCT05638295 | Advanced Malign... Metastatic Mali... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Panitumumab Sotorasib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | NCT06252649 | Metastatic Colo... | FOLFIRI Regimen Sotorasib Panitumumab Bevacizumab-aww... | 18 Years - | Amgen | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | NCT05920356 | Non-Small Cell ... | Sotorasib Pembrolizumab | 18 Years - 100 Years | Amgen | |
| Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants | NCT05045638 | Healthy Partici... | Rosuvastatin Sotorasib | 18 Years - 60 Years | Amgen | |
| Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities | NCT05311709 | Lung Cancer NSCLC, Stage II... NSCLC Stage IV Lung Cancer Sta... Mutation Cancer Cancer, Lung | sotorasib | 18 Years - | Vestre Viken Hospital Trust | |
| Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer | NCT06249282 | Advanced Lung N... Metastatic Lung... Stage III Lung ... Stage IV Lung C... | Biopsy Biospecimen Col... Carfilzomib Computed Tomogr... Echocardiograph... Magnetic Resona... Sotorasib | 18 Years - | City of Hope Medical Center | |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | NCT05251038 | Pancreatic Canc... Unresectable Pa... Metastatic Panc... KRAS P.G12C | Sotorasib Liposomal Irino... 5 Fluorouracil ... Leucovorin (LV) Gemcitabine (GE... Nab paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | NCT04185883 | Advanced Solid ... Kirsten Rat Sar... | Sotorasib Trametinib RMC-4630 Afatinib Pembrolizumab Panitumumab Carboplatin, pe... Atezolizumab Palbociclib MVASI® (bevaciz... TNO155 IV Chemotherapy... IV Chemotherapy... BI 1701963 AMG 404 Everolimus | 18 Years - 100 Years | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
